FDA authorization and Medicare coverage answer different questions. A device company can establish that its product may be marketed without having resolved whether Medicare will cover its intended use. Commercial planning has to account for both decisions.
RAPID seeks to connect those processes earlier. With comments on the August procedural notice due October 13, the useful question this week is how the proposal would work, and which assumptions a manufacturer should avoid building into its business plan.
- Why this matters now
- What actually happened
- The obvious read versus the deeper signal
- Taxonomy: Eligibility, evidence and coverage under RAPID
- The operational framework: Four questions before the pivotal study
- Capital flows, incentives, and bottom-up economics
- The HealthTech Investor’s Signal: Underwriting the coverage milestone
- The counter-thesis: Faster coverage does not settle commercial adoption
- Forward Intelligence: Four observable test indicators
- The Bottom Line for Device Executives and Investors
Why this matters now
A coverage discussion late in development can expose a mismatch between the pivotal study and the population or outcomes relevant to Medicare. Addressing that mismatch may require more evidence. Earlier engagement could help a sponsor understand it while there is still room to adjust the plan.
The opportunity is therefore broader than a shorter period after authorization. Our interpretation is that the proposal could improve the quality of early development decisions, provided the manufacturer can meet its narrow eligibility and evidence conditions.
What actually happened
CMS and FDA announced RAPID on April 23. CMS described the proposed procedure in August, and the August 11 Federal Register notice set an October 13 comment deadline. The close of the comment window is the recent milestone for teams tracking the proposal.
The notice describes a proposed NCD alongside FDA authorization for qualifying devices with sufficient evidence, followed by a goal of roughly 60 days to a final NCD for Class II devices or 90 days for Class III devices. The reviewed sources do not establish a newly published final notice. These are proposed coverage timelines, not guaranteed commercial sales.
The obvious read versus the deeper signal
The surface story is “coverage in two months.” The deeper commercial issue is whether a device enters development with an evidence strategy that can serve both regulatory and coverage decisions.
A final coverage determination is also distinct from the operational work of coding, appropriate payment and getting providers to adopt the product. A manufacturer should identify those separate milestones rather than assigning all revenue risk to one coverage date.
